Search

Abstract Background The prevalence of non‐alcoholic fatty liver disease (NAFLD), which is characterized by hepatic steatosis, inflammation, and advanced fibrosis, is high among type‐2 diabetes mellitus (T2DM) patients. Empagliflozin (EMPA), a sodium‐glucose cotransporter‐2 inhibitor, has been well established to improve glycemic status in T2DM. However, evidence of the desirable effects of EMPA, when added to the standard treatment in diabetics with coexisting NAFLD, has yet to be determined. Objective The main objective of the current study is to explore the benefits of EMPA on hepatic fat content in patients with T2DM and NAFLD, who received metformin (MET) monotherapy. Methods In this open‐label clinical trial study, 60 patients with T2DM and NAFLD were assigned to either the MET + EMPA or MET group in an up‐titrated manner for 24 weeks. Anthropometric characteristics, blood glucose indices, lipid profile, liver enzymes, and steatosis grades were measured at baseline and 24 weeks after the intervention. Results The results showed that in patients with a mean age of 53.26 ± 7.64 who received MET+ EMPA, all the parameters had a greater decrease than the MET group. In addition, the reduction of FBS, BS, HbA1C, TG, and ALT had a statistically significant difference between the two groups after 24 weeks follow‐up (p

Abstract Rosai‐Dorfman disease (RDD), as a lymphoproliferative disorder with unknown etiology, is commonly identified with systemic clinical manifestations in various organs. In this case study, RDD occurrence was reported with an exceedingly liver mass.

Background: To date, the clinical implications of the long-lasting non-alcoholic fatty liver disease (NAFLD) such as the left ventricular diastolic dysfunction (LVDD) in the course of type 2 diabetes mellitus (T2DM) are yet to be determined. The main aim of this study was to investigate the correlation between NAFLD and early LVDD progression along with demographic characteristics. Methods: This cross-sectional study was performed on ninety consecutive diabetic outpatients referred to the endocrinology clinic. Demographic data were collected using a designed checklist. Ultrasound imaging was performed to assess the fatty liver condition. To assess LV diastolic function, echocardiography was performed, using a trans-thoracic tissue Doppler echocardiography. Results: The results showed that the majority of participants were females (61.1%). The fasting blood glucose (FBG, mg/dl) level was 174.65 ±51.1. Also, the mean body mass index (BMI) was 28.92±4.19, which was significantly associated with NAFLD. It has been also estimated that 76.7% and 81.1% of diabetic patients had NAFLD and simultaneous LVDD, respectively. However, the statistical results did not show a significant association between non-progressive NAFLD and LVDD (p